Literature DB >> 20126606

Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.

Claus G Roehrborn1.   

Abstract

Male lower urinary tract symptoms (LUTS) are one of the most common causes for a consultation with a health care provider, and one of the most common causes of male LUTS is benign prostatic hyperplasia (BPH). In recent decades, medical therapy has established itself as viable and cost effective for the majority of men. For the treatment of male LUTS in the United States, the 5 currently available alpha-adrenergic receptor blockers are alfuzosin, doxazosin, silodosin, terazosin, and tamsulosin. alpha-Blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit an early onset of efficacy (within less than 1 week) with regard to both symptoms and flow rate improvement, maintain such improvements in open-label and controlled trials for up to 5 years, and have been shown to prevent symptomatic progression.

Entities:  

Keywords:  Benign prostatic hyperplasia; Lower urinary tract symptoms; α-Blocker

Year:  2009        PMID: 20126606      PMCID: PMC2812889     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  44 in total

Review 1.  Medical therapy to facilitate the passage of stones: what is the evidence?

Authors:  Christian Seitz; Evangelos Liatsikos; Francesco Porpiglia; Hans-Göran Tiselius; Ulrike Zwergel
Journal:  Eur Urol       Date:  2009-06-21       Impact factor: 20.096

Review 2.  Alpha blockers prior to removal of a catheter for acute urinary retention in adult men.

Authors:  Hans-Joerg Zeif; Kesavapillai Subramonian
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

3.  Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels.

Authors:  M S Smith; U B Schambra; K H Wilson; S O Page; D A Schwinn
Journal:  Brain Res Mol Brain Res       Date:  1999-01-08

4.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

Review 5.  Urodynamic effects of various treatment modalities for benign prostatic hyperplasia.

Authors:  J L Bosch
Journal:  J Urol       Date:  1997-12       Impact factor: 7.450

6.  A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.

Authors:  B Djavan; M Marberger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

7.  Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.

Authors:  S A McNeill; T B Hargreave; Claus G Roehrborn
Journal:  Urology       Date:  2005-01       Impact factor: 2.649

8.  Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs.

Authors:  K Akiyama; H Noto; O Nishizawa; K Sugaya; R Yamagishi; M Kitazawa; S Tsuchida
Journal:  Int J Urol       Date:  2001-04       Impact factor: 3.369

9.  alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.

Authors:  C Rossi; B B Kortmann; G S Sonke; D L Floratos; L A Kiemeney; H Wijkstra; J J de la ROSETTE
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

10.  Micturition in conscious rats with and without bladder outlet obstruction: role of spinal alpha 1-adrenoceptors.

Authors:  O Ishizuka; K Persson; A Mattiasson; A Naylor; M Wyllie; K Andersson
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

View more
  19 in total

1.  Sexual impact of treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Herbert J Wiser; Tobias S Köhler
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

2.  Isoform-specific dynamic translocation of PKC by α1-adrenoceptor stimulation in live cells.

Authors:  Jin O-Uchi; Jaime Sorenson; Bong Sook Jhun; Jyotsna Mishra; Stephen Hurst; Kaleef Williams; Shey-Shing Sheu; Coeli M B Lopes
Journal:  Biochem Biophys Res Commun       Date:  2015-08-12       Impact factor: 3.575

3.  Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration.

Authors:  Yu Chen; Grazyna Palczewska; Debarshi Mustafi; Marcin Golczak; Zhiqian Dong; Osamu Sawada; Tadao Maeda; Akiko Maeda; Krzysztof Palczewski
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

4.  Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it.

Authors:  Sebastiano Spatafora; Antonio Casarico; Andrea Fandella; Caterina Galetti; Rodolfo Hurle; Elisa Mazzini; Ciro Niro; Massimo Perachino; Roberto Sanseverino; Giovanni Luigi Pappagallo
Journal:  Ther Adv Urol       Date:  2012-12

Review 5.  Update on the sexual impact of treatment for benign prostatic hyperplasia.

Authors:  John Roger Bell; Eric Laborde
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

6.  Management of urinary incontinence.

Authors:  George A Demaagd; Timothy C Davenport
Journal:  P T       Date:  2012-06

Review 7.  Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.

Authors:  Charles Welliver; Michael Butcher; Yogitha Potini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

Review 8.  Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.

Authors:  Hui Ding; Wan Du; Zi-Zhen Hou; Han-Zhang Wang; Zhi-Ping Wang
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

Review 9.  Silodosin in the treatment of benign prostatic hyperplasia.

Authors:  Maxime Rossi; Thierry Roumeguère
Journal:  Drug Des Devel Ther       Date:  2010-10-27       Impact factor: 4.162

10.  The use of primary and secondary doxazosin XL (8 mg) in the treatment of benign prostate hyperplasia: Is there a new approach in the event of alpha-blocker failure?

Authors:  Muhammet İhsan Karaman; Zülfü Sertkaya; Orhan Koca; Mehmet Akyüz; Mustafa Güneş; Metin İshak Öztürk
Journal:  Turk J Urol       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.